Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Baotou
Clinical trial register · China

Clinical Trials in Baotou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19257 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:17 UTC
19257
Studies in scope
all four open statuses
11829
Recruiting now
open to new participants
2031
Lead sponsors
across recruiting studies
Top sites
Beijing 5598 Shanghai 3888 Guangzhou 3358 Hangzhou 1831 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca17 Novartis Pharmaceuticals6 Xiaguang Duan6 Boehringer Ingelheim4 Eli Lilly and Company3 Beijing Tiantan Hospital3 Sanofi3 Alexion Pharmaceuticals, Inc.2 Xuanwu Hospital, Beijing2 Inner Mongolia Baogang Hospital2 Janssen Research & Development, LLC2 Vertex Pharmaceuticals Incorporated1 Biotech Pharmaceutical Co., Ltd.1 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1 Takeda1 EMD Serono Research & Development Institute, Inc.1 Eisai Inc.1 China National Center for Cardiovascular Diseases1 Peking University Cancer Hospital & Institute1 Chengdu Kangnuoxing Biopharma,Inc.1 Changhai Hospital1 UCB Biopharma SRL1 China-Japan Friendship Hospital1 ADARx Pharmaceuticals, Inc.1 Tianjin Medical University Cancer Institute and Hospital1 Show all 43
Site location
Beijing5598 Shanghai3888 Guangzhou3358 Hangzhou1831 Wuhan1343 Chengdu1309 Nanjing1213 Changsha1159 Chongqing1083 Fuzhou1042 Tianjin939 Zhengzhou928 Hefei906 Jinan791 Changchun640 Shenzhen585 Harbin549 Nanchang449 Xi'an443 Nanning442 Suzhou431 Shenyang406 Xiamen392 Shijiazhuang351 Lanzhou273 Show all 624
All 624 locations
Target enrolment
to

Trials with a site in Baotou

82 of 19257 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
China National Center for Cardiovascular Diseases
Phase 3
270
Beijing, Guangzhou, Shenzhen, Zhangjiakou, Xinxiang, Zhengzhou, Wuhan, Baotou
2026-11-01
Not yet open
Beijing Tiantan Hospital
Not applicable
570
Beijing, Baotou
2026-10-01
Recruiting
AstraZeneca
Phase 3
2,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2026-09-01
Not yet open
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
NCT07833098Hypertension, Resistant Hypertension, Uncontrolled Hypertension
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase 2
240
Baotou, Beijing, Changsha, Chengdu, Chongqing, Daqing, Hebei, Hengyang
2026-09
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Baoding, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu
2026-08-24
Recruiting
AstraZeneca
Phase 3
351
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Hefei, Huangshi
2026-08-21
Recruiting
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.
Phase 3
550
Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Baotou, Chifeng, Yinchuan, Jinan
2026-08-18
Recruiting
Chengdu Kangnuoxing Biopharma,Inc.
Phase 3
136
Beijing, Langfang, Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Zhengzhou, Baotou
2026-08-13
Recruiting
Eli Lilly and Company
Phase 2
606
Baotou, Beijing, Chengdu, Guangzhou, Jiangyin, Jinan, Pingxiang, Shanghai
2026-08-07
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
56
Baotou, Tongliao, Taiyuan, Tianjin
2026-08-01
Recruiting
AstraZeneca
Phase 3
800
Baotou, Binzhou, Cangzhou, Changsha, Chengdu, Ganzhou, Haikou, Hangzhou
2026-07-06
Recruiting
AstraZeneca
Phase 3
2,000
Baotou, Beijing, Changde, Changsha, Changzhou, Chengdu, Chenzhou, Chifeng
2026-07-06
Recruiting
Harbin Medical University
Not applicable
150
Fuzhou, Nanning, Shijiazhuang, Harbin, Qiqihar, Wuhan, Baotou, Hohhot
2026-06-10
Recruiting
Chinese Adults With Kidney Disease
NCT07522099Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
DrugTelitacicept
ADARx Pharmaceuticals, Inc.
Phase 2
30
Shenzhen, Guiyang, Zhengzhou, Baotou, Wuxi, Yantai, Beijing, Shandong
2026-05-21
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Beijing, Lanzhou, Foshan, Guangzhou, Harbin, Changsha, Baotou, Nanjing
2026-05-11
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou
2026-05-11
Recruiting
Xuanwu Hospital, Beijing
Not applicable
264
Beijing, Fuzhou, Shijiazhuang, Harbin, Nanyang, Zhengzhou, Baotou, Xi'an
2026-04-15
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Baotou, Nanjing, Suzhou, Changchun
2026-04-01
Active, closed
Sanofi
Phase 3
59
Baotou, Beijing, Chengdu, Jinan, Jingzhou, Nanning, Shenyang, Taiyuan
2026-03-12
Recruiting
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
Boehringer Ingelheim
Phase 3
286
Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou
2026-02-16
Recruiting
Danyang Huichuang Medical Equipment Co., Ltd.
Phase 3
320
Beijing, Shijiazhuang, Baotou, Suzhou, Xi'an, Shanghai, Taiyuan, Tianjin
2025-12-10
Active, closed
Dr. Willmar Schwabe GmbH & Co. KG
Phase 4
400
Anyang, Baotou, Beijing, Benxi, Chenzhou, Chifeng, Dalian, Harbin
2025-11-28
Active, closed
Kylonova (Xiamen) Biopharma co., LTD.
Phase 2
204
Beijing, Baotou, Changde, Chongqing, Dali, Daqing, Guangzhou, Harbin
2025-10-29
Recruiting
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
Recruiting
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
Changhai Hospital
Not applicable
1,250
Baotou, Beijing, Hangzhou, Hunan, Lanzhou, Shandong, Shanghai, Yunnan
2025-10-13
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
30
Baotou, Beijing, Guangzhou, Shenzhen
2025-09-19
Recruiting
Sanofi
Phase 3
942
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian
2025-09-17
Active, closed
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Recruiting
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangdong, Guangzhou, Shenzhen, Changsha, Baotou
2025-07-15
Recruiting
AstraZeneca
Phase 2
987
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-06-27
Active, closed
Novartis Pharmaceuticals
Phase 4
1,590
Anqing, Beijing, Chongqing, Longyan, Jiamusi, Zhengzhou, Baotou, Shenyang
2025-06-17
Recruiting
AstraZeneca
Phase 3
15,100
Anqing, Anyang, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha
2025-06-04
Recruiting
Pfizer
Phase 2
252
Beijing, Guangzhou, Baotou, Hohhot, Najing, Nanjing, Xuzhou, Nanchang
2025-05-20
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
Baotou, Beijing, Changchun, Guangzhou, Harbin, Kaili, Linfen, Nanyang
2025-05-15
Recruiting
Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort
NCT06963489Large Vessel Occlusion, Acute Ischemic Stroke
First Affiliated Hospital of Wannan Medical College
Observational
500
Wuhu, Baotou, Jinan, Henan, Beijing
2025-04-27
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
Beijing, Guangzhou, Guiyang, Harbin, Luoyang, Nanyang, Zhuzhou, Baotou
2025-04-24
Recruiting
Peking University Cancer Hospital & Institute
Phase 1/2
42
Neimeng, Baoding, Baotou, Beijing, Dalian, Tianjin
2025-04-08
Recruiting
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Recruiting
AstraZeneca
Phase 3
11,300
Baotou, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng
2025-03-14
Recruiting
AstraZeneca
Phase 3
5,000
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan
2025-03-03
Active, closed
Sanofi
Phase 3
216
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Jinan, Jingzhou, Nanning
2025-02-06
Not yet open
Inner Mongolia Baogang Hospital
Not applicable
120
Baotou
2025-02-01
Not yet open
Regional Anesthesia Techniques in Breast Surgery
NCT06779656Augmentation, Fibroadenoma, Mastectomy
Xiaguang Duan
Not applicable
180
Baotou
2025-02-01
Not yet open
Xiaguang Duan
Not applicable
120
Baotou
2025-02-01
Not yet open
Desflurane Potentially Induces Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Perioperative Procedures by Modulating Cdc42 and Clock Proteins
NCT06772558Avascular Necrosis of the Femoral Head, Coronary Artery Disease (CAD), Benign Prostatic Hyperplasia (BPH), Cholecystitis
DrugDesflurane
Xiaguang Duan
Not applicable
60
Baotou
2025-02-01
Not yet open
Inner Mongolia Baogang Hospital
Not applicable
240
Baotou
2025-02-01
Not yet open
Enhanced Recovery After Urologic Surgery
NCT06789744Circumcision, Hydrocelectomy, Hernia, Renal Cyst
DrugFentanyl
Xiaguang Duan
Not applicable
150
Baotou
2025-02-01
Not yet open
Xiaguang Duan
Not applicable
60
Baotou
2025-02-01
Not yet open
Xiaguang Duan
Not applicable
150
Baotou
2025-01-20
Recruiting
China-Japan Friendship Hospital
Not applicable
400
Xingtai, Zhengzhou, Baotou, Jinan, Datong, Kunming, Beijing
2025-01-01
Not yet open
Sinocelltech Ltd.
Phase 1/2
99
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning
2025-01
Active, closed
AstraZeneca
Phase 2/3
432
Baotou, Beijing, Bengbu, Changchun, Changde, Changsha, Changzhou, Chengdu
2024-12-06
Recruiting
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Dalian
2024-06-17
Recruiting
AstraZeneca
Phase 3
1,000
Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou
2024-06-17
Recruiting
AstraZeneca
Phase 3
3,850
Baotou, Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Guangzhou
2024-04-12
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2024-03-29
Recruiting
AstraZeneca
Phase 3
5,250
Anning, Anyang, Baotou, Beijing, Changsha, Changzhi, Chengdu, Chifeng
2024-02-21
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Active, closed
AstraZeneca
Phase 3
1,835
Baotou, Beijing, Changsha, Chengdu, Chongqing, Deyang, Foshan, Guangzhou
2023-11-07
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Active, closed
Bio-Thera Solutions
Phase 2
162
Baotou, Beijing, Changsha, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou
2023-08-01
Active, closed
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
80
Baotou, Beijing, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou, Hengyang
2023-07-06
Recruiting
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
200
Luoyang, Wuhan, Nanjing, Nanchang, Changchun, Dalian, Baotou, Kunming
2023-05-11
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
300
Beijing, Guangzhou, Luoyang, Hengshui, Daqing, Wuhan, Baotou, Huai'an
2023-04-06
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Anyang, Baoji, Baotou, Beijing, Changchun, Changsha, Chengdu, Chenzhou
2023-02-15
Active, closed
A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion
NCT05615038Basilar Artery Occlusion, Endovascular Treatment
Beijing Tiantan Hospital
Not applicable
338
Hefei, Beijing, Anyang, Zhangzhou, Baotou
2022-11-07
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
381
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Recruiting
Dimerix Bioscience Pty Ltd
Phase 3
286
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Hohhot, Jinan, Nanchang
2022-05-30
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing
2021-12-16
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Baotou, Beijing, Cangzhou, Changchun, Changsha, Chaoyang District, Chengdu, Chongqing
2021-08-14
Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
NCT04948749ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke
Beijing Tiantan Hospital
Not applicable
358
Beijing, Cangzhou, Tangshan, Xingtai, Wuhan, Baotou, Hohhot, Tongliao
2021-07-02
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Baoding, Baotou, Beijing, Bengbu, Changchun, Changzhou, Chengdu, Chongqing
2021-06-17
Active, closed
Biotech Pharmaceutical Co., Ltd.
Phase 4
171
Baotou
2021-05-15
Active, closed
Novartis Pharmaceuticals
Phase 3
345
Lanzhou, Foshan, Guangzhou, Shijiazhuang, Baotou, Hohhot, Nanjing, Nantong
2021-03-01
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Dongguan, Fuzhou, Baotou, Nanjing, Nantong, Shanghai, Chengdu, Ürümqi
2020-12-11
Active, closed
Eisai Inc.
Phase 3
1,906
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Baotou, Nanjing, Changchun
2019-03-27
Rows per page Showing 1–82 of 82
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-china/city/baotou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,257 studies in total at the last sync on 13 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 82 of those studies with a site in Baotou.

How many clinical trials are recruiting in Baotou?

44 of the 82 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:17 UTC sync. A further 13 have not yet opened recruitment, 24 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Baotou), 82 studies
PhaseStudiesRecruitingShare
Phase 3412550%
Not applicable17720.7%
Phase 213815.9%
Phase 1/2313.7%
Phase 2/3323.7%
Phase 4303.7%
Observational212.4%

Most active sponsors

Lead sponsors with the most studies (Baotou)
Lead sponsorStudiesRecruiting
AstraZeneca1713
Novartis Pharmaceuticals60
Xiaguang Duan60
Boehringer Ingelheim44
Beijing Tiantan Hospital31
Eli Lilly and Company32
Sanofi31
Alexion Pharmaceuticals, Inc.21
Inner Mongolia Baogang Hospital20
Janssen Research & Development, LLC20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.